Analytical Data
-
Gene name
Mageh1
- Application
-
Alternative Names
(MAGE-H1 antigen)
-
Species
Mouse
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9NWG9
-
Expression Region
1-218aa
-
Molecular Weight
30.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Mageh1 (Melanoma-associated antigen H1) is a member of the MAGE (melanoma-associated antigen) family, which is known for its role in tumorigenesis and immune response. Discovered in the context of melanoma, Mageh1 has garnered attention due to its potential as a target for cancer immunotherapy, particularly in solid tumors. The protein is believed to be involved in the modulation of cell cycle regulation and apoptosis, making it a critical player in cancer development. Research has focused on its expression patterns, as Mageh1 is typically found in various tumors but not in most normal tissues, highlighting its potential as a tumor-specific antigen. Advances in recombinant protein technology have enabled the production of Mageh1 in a laboratory setting, facilitating studies on its structure, function, and interactions with immune cells. Understanding the properties of Mageh1 recombinant protein is essential for the development of therapeutic strategies, including peptide-based vaccines and adoptive T-cell therapies. Current studies aim to elucidate the immunogenicity of Mageh1 and its potential to stimulate an effective antitumor immune response, paving the way for novel cancer immunotherapies that harness the body's immune system to target and eliminate malignant cells.
